Submit your email to push it up the queue
Cubist Pharmaceuticals LLC, headquartered in the United States, is a prominent player in the biopharmaceutical industry, specialising in the development and commercialisation of innovative therapies for infectious diseases. Founded in 1992, the company has achieved significant milestones, including the launch of groundbreaking antibiotics that address critical unmet medical needs. With a strong focus on research and development, Cubist Pharmaceuticals offers a unique portfolio of products designed to combat resistant bacterial infections. Their commitment to advancing healthcare is reflected in their robust pipeline and strategic partnerships within the industry. Recognised for its contributions to public health, Cubist has established a solid market position, making it a trusted name among healthcare professionals and patients alike.
How does Cubist Pharmaceuticals LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Cubist Pharmaceuticals LLC's score of 69 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cubist Pharmaceuticals LLC, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Merck & Co., Inc., and any climate commitments or emissions data may be inherited from this parent organisation. Cubist Pharmaceuticals has not established its own reduction targets or climate pledges. However, it is important to note that the climate initiatives and performance metrics may align with those of Merck & Co., Inc., which is actively engaged in various sustainability efforts. These efforts include participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are led by Merck. As a subsidiary, Cubist Pharmaceuticals may benefit from the broader climate strategies implemented by Merck, which include commitments to reduce greenhouse gas emissions across Scope 1, 2, and 3 categories. However, specific details regarding these initiatives and their impact on Cubist's operations are not disclosed. In summary, while Cubist Pharmaceuticals LLC does not provide specific emissions data or reduction targets, it is positioned within a corporate family that is committed to addressing climate change through established initiatives and frameworks.
Access structured emissions data, company-specific emission factors, and source documents
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | 5,760,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cubist Pharmaceuticals LLC is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.